Small molecule · Inhibitor of anaplastic lymphoma kinase (ALK) · developed by Nuvalent
Neladalkib (NVL-655) is an orally bioavailable, brain-penetrant small molecule inhibitor of anaplastic lymphoma kinase (ALK). It targets ALK fusion proteins and activating mutations, including acquired resistance mutations such as G1202R and compound mutations. The drug is studied in ALK-positive non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06765109 | Phase 3 | Non-small Cell Lung Cancer | Recruiting | NUVL |
| NCT06834074 | N/A | Non Small Cell Lung Cancer | Available | NUVL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anaplastic Lymphoma Kinase-positiveNon-small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)
Updated Oct 3, 2026. Something wrong or missing? Report it on the NUVL page.
See NUVL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NUVL catalysts and pipeline →